Literature DB >> 10873788

Anti-Gag cytolytic T lymphocytes specific for an alternative translational reading frame-derived epitope and resistance versus susceptibility to retrovirus-induced murine AIDS in F(1) mice.

S M Mayrand1, P A Healy, B E Torbett, W R Green.   

Abstract

Murine AIDS (MAIDS) develops in susceptible mouse strains after infection with the LP-BM5 murine leukemia virus complex that contains causative defective, and ecotropic helper, retroviruses. We previously demonstrated that the MAIDS-resistant H-2(d) strains BALB/cByJ and C57BL/KsJ generate MHC class I (K(d)) restricted virus-specific CD8(+) cytolytic T lymphocytes (CTLs) that lyse cells expressing either defective or ecotropic gag proteins. In contrast, the congenic BALB.B and closely related C57BL/6J MAIDS-susceptible H-2(b) strains were unable to serve as a source of gag-specific CTLs (Schwarz and Green, 1994), suggesting that anti-gag CTLs might provide a basis for resistance to MAIDS. Although its susceptibility to MAIDS was unknown, the (BALB/c x C57BL/6J) F(1) (CBY6F(1)) strain could also produce H-2(d)-, but not H-2(b)-, restricted, anti-gag CTLs (Schwarz and Green, 1994). Because of this correlation between anti-gag CTLs and resistance to MAIDS, it was important to provide more direct evidence in support of CTL-mediated protection and to determine both the fine specificity of CByB6F(1) anti-gag CTLs, in comparison with the resistant C57BL/Ks and BALB/c strains, and the susceptibility of this F(1) strain to LP-BM5-induced MAIDS. We report here that no symptoms of MAIDS were observed in CBY6F(1) (H-2(dxb)) mice. For F(2) mice, in contrast to the high susceptibility of H-2(b/b) mice, 77% of H-2(d/d) and 81% of H-2(b/d) F(2) mice did not exhibit MAIDS after LP-BM5 infection. These results are in contrast to other published studies that concluded that susceptibility, rather than resistance, is dominant in F(1) (resistant x susceptible or susceptible x resistant) mice. We also show that CBY6F(1) anti-gag CTLs exhibit a fine specificity shared by the MAIDS-resistant BALB/c and C57BL/Ks strains, that is, the immunodominant gag epitope, SYNTGRFPPL, encoded by an alternative open reading frame. Together with our direct demonstration here that in vivo monoclonal antibody (mAb) depletion of CD8(+) T cells converts genetically resistant mice to MAIDS susceptibility, these data on the ability to mount anti-ORF2/SYNTGRFPPL, gag-specific CTL responses strongly suggest that CTLs are a primary factor in determining MAIDS resistance. Accordingly, given the K(d)-restricted nature of the CTLs, the main genetic determinant of resistance appeared to be the codominant expression of the resistant H-2(d) haplotype. Interestingly, however, 19% of H-2(d/b) and 23% of the H-2(d/d) F(2) mice had at least one clinical aspect of MAIDS, suggesting that a non-MHC genetic determinant(s) can negatively influence T-cell protection and thus disease outcome Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10873788     DOI: 10.1006/viro.2000.0339

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  10 in total

1.  Essential roles for CD8+ T cells and gamma interferon in protection of mice against retrovirus-induced immunosuppression.

Authors:  Ulf Dittmer; Brent Race; Karin E Peterson; Ingunn M Stromnes; Ronald J Messer; Kim J Hasenkrug
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

2.  Role of a cytotoxic-T-lymphocyte epitope-defined, alternative gag open reading frame in the pathogenesis of a murine retrovirus-induced immunodeficiency syndrome.

Authors:  Arti Gaur; William R Green
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

3.  Immunotherapy of murine retrovirus-induced acquired immunodeficiency by CD4 T regulatory cell depletion and PD-1 blockade.

Authors:  Wen Li; William R Green
Journal:  J Virol       Date:  2011-09-14       Impact factor: 5.103

4.  Impaired memory CD8 T cell responses against an immunodominant retroviral cryptic epitope.

Authors:  Melanie R Rutkowski; Cynthia A Stevens; William R Green
Journal:  Virology       Date:  2011-02-04       Impact factor: 3.616

5.  Alternative translational reading frames as a novel source of epitopes for an expanded CD8 T-cell repertoire: use of a retroviral system to assess the translational requirements for CTL recognition and lysis.

Authors:  Timothy L Carlson; Kathy A Green; William R Green
Journal:  Viral Immunol       Date:  2010-12       Impact factor: 2.257

6.  Myeloid-derived suppressor cells in murine retrovirus-induced AIDS inhibit T- and B-cell responses in vitro that are used to define the immunodeficiency.

Authors:  Kathy A Green; W James Cook; William R Green
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

7.  Novel role of CD8(+) T cells and major histocompatibility complex class I genes in the generation of protective CD4(+) Th1 responses during retrovirus infection in mice.

Authors:  Karin E Peterson; Ingunn Stromnes; Ron Messer; Kim Hasenkrug; Bruce Chesebro
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

8.  Defining the mechanism(s) of protection by cytolytic CD8 T cells against a cryptic epitope derived from a retroviral alternative reading frame.

Authors:  Melanie R Rutkowski; On Ho; William R Green
Journal:  Virology       Date:  2009-06-18       Impact factor: 3.616

9.  The programmed death-1 and interleukin-10 pathways play a down-modulatory role in LP-BM5 retrovirus-induced murine immunodeficiency syndrome.

Authors:  Kathy A Green; Taku Okazaki; Tasuku Honjo; W James Cook; William R Green
Journal:  J Virol       Date:  2007-12-19       Impact factor: 5.103

10.  The HIV-1 antisense protein (ASP) induces CD8 T cell responses during chronic infection.

Authors:  Anne Bet; Emmanuel Atangana Maze; Anju Bansal; Sarah Sterrett; Antoine Gross; Stéphanie Graff-Dubois; Assia Samri; Amélie Guihot; Christine Katlama; Ioannis Theodorou; Jean-Michel Mesnard; Arnaud Moris; Paul A Goepfert; Sylvain Cardinaud
Journal:  Retrovirology       Date:  2015-02-10       Impact factor: 4.602

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.